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Abstract Sphingolipid breakdown products are now being 
recognized to play a dual role in cellular signalling, acting as 
intracellular as well as extracellular signalling molecules. Both 
types of action may even be found with one sphingolipid species. 
The recent demonstration of G protein-coupled receptors with 
high affinity for sphingosine 1-phosphate and sphingosyl-
phosphorylcholine has been followed by the discovery of several 
novel sphingolipid actions, such as regulation of heart rate, 
oxidative burst, neurite retraction or platelet activation. Ligand 
profiles and concentration-response relationships suggest the 
existence of putative sphingolipid receptor subtypes. Against this 
background, several observations on supposed sphingolipid 
second messenger actions deserve a new evaluation. 
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1. Introduction 
Many extracellular signalling molecules such as hormones, 
neurotransmitters and growth factors act via specific cell sur-
face receptors which often regulate cellular functions by in-
ducing breakdown of certain complex plasma membrane lip-
ids. Since the 1980s, several second messenger molecules 
derived from membrane glycerophospholipids have been iden-
tified [1]. However, lipid signalling is not restricted to second 
messenger functions. Several lipid messengers derived from 
glycerophospholipids act as extracellular signalling molecules, 
such as the eicosanoids, platelet-activating factor and lyso-
phosphatidic acid (LPA). Despite their lipophilic character, 
which should possibly allow easy access to the cell interior, 
these lipids act via specific cell surface receptors, which are 
mainly of the G protein-coupled receptor superfamily [2]. 
Much less is known about the signalling properties of an-
other major group of ubiquitously occurring membrane lipids, 
the sphingolipids. Sphingolipids are composed of three basic 
constituents, a sphingoid base, i.e. a long chain aliphatic 2-
amino-l,3-diol, which predominantly is sphingosine, an 
amide-linked fatty acid, and a polar head group. The head-
group distinguishes between neutral sphingolipids like ceram-
ide, phosphosphingolipids like sphingomyelin, and glyco-
sphingolipids like cerebrosides and gangliosides. The 
complex structure of the members of this lipid class ideally 
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suits them for a diversity of cellular functions [3]. Sphingolipid 
degradation products which are presently regarded as signal-
ling molecules are ceramide, ceramide 1-phosphate, sphingo-
sine, sphingosine 1-phosphate (SPP) and sphingosylphospho-
rylcholine (SPPC). Galactosylsphingosine (psychosine) as well 
as glucosylsphingosine (glucopsychosine, GPS) should per-
haps be added to the list. Fig. 1 gives a short overview of 
the structures and some of the metabolic pathways producing 
and degrading the respective molecules, which are probably 
subject to complex cellular regulations. A more comprehen-
sive presentation of sphingolipid metabolism can be found in 
[4]. 
Sphingolipid breakdown products have been implicated as 
second messengers in the regulation of cell growth, differen-
tiation and programmed cell death. Most details are known 
about the sphingomyelin cycle leading to receptor-mediated 
production of ceramide. Several intracellular targets of ceram-
ide possibly involved in ceramide-induced apoptosis have re-
cently been identified. This topic is reviewed in [5-8] and will 
not be covered here. Publications dealing with second messen-
ger actions of sphingosine, SPP and SPPC have been summar-
ized in [4,9-13]. Very recently, however, high-affinity plasma 
membrane receptors for SPP and SPPC have been discovered 
[14-17]. In parallel, progress is made in characterizing the 
regulation of SPP production [18] and defining intracellular 
SPP and/or SPPC targets [19,20]. Sphingolipids have thus to 
be regarded as intracellular as well as intercellular messengers. 
This will be the topic of the present minireview. 
2. G protein-coupled sphingolipid receptors 
2.1. Evidence for specific G protein-coupled sphingolipid 
receptors 
Hints pointing to the existence of sphingolipid receptors 
had been obtained from sporadic reports that the actions of 
sphingosine, SPP or SPPC could be attenuated by treatment 
with pertussis toxin (PTX). This toxin prevents receptor cou-
pling to G proteins of the G; family, thus blocking cellular 
signalling by these receptors [21]. For example, PTX partially 
inhibited sphingosine-induced inositol phosphate accumula-
tion in dermal fibroblasts [22]. In thyroid FRTL-5 cells, 
PTX attenuated the increase in intracellular Ca2+ concentra-
tion ([Ca2+];) in response to SPPC but not to sphingosine [23]. 
In Swiss 3T3 fibroblasts, PTX inhibited 70-80% of SPP-stimu-
lated mitogen-activated protein kinase activity and reduced 
SPP-induced inositol phosphate production, increase in 
[Ca2+]i, DNA synthesis as well as DNA binding activity of 
activator protein-1 [24,25]. Here, SPP was also found to in-
hibit forskolin-stimulated cAMP production in a PTX-sensi-
tive manner, which is a typical response of G;-coupled recep-
tors. In addition to the PTX sensitivity, the high potency of 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00320-7 
D. Meyer zu Heringdorf et al.lFEBS Letters 410 (1997) 34-38 35 
Sphingomyelin / 
' cHj^OP-O-CHOLINE 
H "NH ° H 
Ceramide 
K „OH 
CH,OH 
o=a 
Sphingolipid 
Ceramide 
A/-deacylase I 
Sphingomyelinase 
H NH 
0 = C 
Ceramidase 
/v-uecit jyicisfc! j n 
A A A A A A A X 0 ^ 
H NH OH 
Sphi ngosyl phosphoryl chol i ne 
CHOLINE 
t 
Hi OH 
AAAAAA/V^ 
Sphingosine 
OH, OH 
H " NH0 
Sphingosine kinase 
CH 
I 
P-OH 
II 
H NH 
Sphingosine-1 -phosphate 
Fig. 1. A summary of sphingomyelin metabolism generating biologically active sphingolipid metabolites. 
exogenously added SPP, in the low nanomolar range, found in 
some cell types suggested the participation of specific mem-
brane receptors in SPPs action. For example, SPP was re-
ported to inhibit platelet-derived growth factor (PDGF)-in-
duced migration of human aortic smooth muscle cells with 
an EC50 of 16 nM [26]. Similarly, inhibition of B16 melanoma 
cell motility was maximal at 10-100 nM SPP [27,28]. Finally, 
the observation made in several cell types that the action of 
SPP was subject to desensitization pointed towards a receptor-
mediated process. 
Although these data were suggestive of the existence of 
specific membrane receptors for these sphingolipids, they 
could not resolve the question whether sphingolipids act by 
direct G protein activation or by receptor stimulation. This 
dilemma was solved by the observation that SPP activated 
muscarinic K+ current (IK(ACII)) m atrial myocytes [29]. The 
channel is directly inhibited by Py-subunits released from Gj 
proteins which in turn are activated by plasma membrane 
receptors such as muscarinic acetylcholine receptors, thus rep-
resenting a signalling system composed of only three mem-
brane components [30]. SPP activated this current with a 
high potency (EC50 ~ 1 nM) in a completely PTX-sensitive 
manner [29]. This observation thus made it possible to identify 
the site of SPPs acton. Using inside-out patches, it was dem-
onstrated that SPP activated the current only in the presence 
of GTP, required for G; activation, and, most importantly, 
only when SPP was applied to the extracellular face of the 
plasma membrane [14]. The high potency of SPP combined 
with the absence of LPA receptors strongly suggests that SPP 
is an endogenous ligand of this G;-coupled membrane recep-
tor. 
Further proofs for sphingolipid plasma membrane receptors 
followed soon. In N1E-115 neuronal cells, SPP caused neurite 
retraction with an EC50 of 1.5 nM [17]. This action of SPP 
was not PTX-sensitive, was subject to desensitization and was 
only observed when SPP was applied extracellularly, whereas 
microinjection of SPP had no effect. In atrial myocytes, 
iK(ACh) w a s n ° t only activated by SPP but also by SPPC. 
Importantly, this action was highly stereoselective, the natu-
rally occurring erythro-isomer being ~400 times more potent 
than the threo-isomer of SPPC [31]. This observation also 
strongly argues against a non-selective detergent action of 
the amphipathic sphingolipids; detergent-like actions, how-
ever, may well occur at much higher concentrations. Sphingo-
lipid receptors are apparently not restricted to those for SPP 
and SPPC only. In insulinoma cells, GPS inhibited L-type 
Ca2+ currents, however, only when applied extracellularly, 
whereas inclusion of GPS into the patch pipette solution 
had no effect. This Ca2+ channel inhibition was PTX-insensi-
tive, but could be blocked by intracellular GDP(3S, indicating 
involvement of PTX-insensitive G proteins [32]. 
2.2. Occurrence and functions of sphingolipid receptors 
Until recently, sphingolipids were considered to be involved 
only in regulation of mitogenesis, cell differentiation and cell 
growth or apoptosis [4,12,13]. Testing the concept of specific 
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Table 1 
Putative sphingolipid receptor subtypes 
Receptor subtype 
I 
II 
Ilia 
Illb 
Sphingolipid potency (EC50) 
SPP 
1.2 nM 
2.0 nM 
0.8 nM 
1.5 nM 
> 1 0 u M 
>10 uM 
SPPC 
1.5 nM 
0.5 uM 
0.3 uM 
n.d. 
1.5 uM 
5 uM 
GPS, PS 
>10 uM 
> 1 0 u M 
>10 uM 
n.d. 
~ 8 uM 
4 uM 
PTX 
+ 
+ 
+ 
+ 
+ 
— 
+ 
+ 
— 
Cell type 
atrial myocytes 
HEK-293 cells 
endothelial cells 
VSMC 
dermal fibroblasts 
N1E-115 
neutrophils 
HL-60 cells'1 
insulinoma cells 
Response 
activation of IK(ACII) 
[Ca2+]; increase 
neurite retraction 
O2 production 
[Ca2+]; increase 
inhibition of VOCC 
Reference 
[14,31] 
[14] 
[16] 
[26]* 
* 
[17] 
[15]* 
[32] 
PS, psychosine; PTX, + and —, PTX-sensitive and -insensitive; HEK-293, human embryonic kidney; VSMC, vascular smooth muscle cells; N1E-
115, mouse neuronal cells; VOCC, voltage-operated calcium channels; *own unpublished observations; n.d., not determined; "but see [56,57], in 
which PTX-sensitive [Ca2+]; increase by SPP, SPPC and PS in HL-60 cells has been reported. The difference is probably due to different subclones 
of HL-60 cells. 
membrane receptors for sphingolipids has already been fruit-
ful in that it has led to the discovery of several novel sphin-
golipid actions. Thus, SPP and SPPC, both potently activating 
atrial IK(ACII)> m a v be involved in regulation of heart rate 
[29,31]. The physiological role of the observed sphingolipid 
effects on vascular cells deserves specific attention. SPP (and 
SPPC) potently increased [Ca2+]j in endothelial cells of differ-
ent origin such as bovine aorta [16] and human umbilical vein 
(own unpublished observations) as well as in vascular smooth 
muscle cells [26], suggesting that SPP plays a delicate role in 
hemodynamics and regulation of vascular tone and blood 
pressure in vivo, which needs to be demonstrated. A source 
for SPP in the vascular system may be thrombin-activated 
platelets, which have recently been shown to release internally 
stored SPP extracellularly upon stimulation [33,34]. Platelets 
themselves are also activated by SPP, however, apparently by 
binding to the platelet LPA receptor [34]. Induction of neurite 
retraction by SPP observed in N1E-115 cells may be a hint 
towards a role of this sphingolipid in neuropathology, with 
blood-borne SPP possibly contributing to damage of neuronal 
cells under conditions of blood-brain barrier breakdown 
where axon regeneration is often impaired [17]. 
Another cellular function potently affected by SPP is cell 
motility, which is essential for many physiological and patho-
logical processes such as wound healing, angiogenesis and 
tumor metastasis [27,28,35]. Even mitogenesis induced by 
SPP, previously thought to be an intracellular SPP action, 
may be mediated by a membrane receptor, as the mitogenic 
response and DNA synthesis induced by SPP in Swiss 3T3 
cells was inhibited by PTX [24,25]. Similarly, as demonstrated 
in airway smooth muscle cells, SPP-induced activation of ex-
tracellular signal-regulated kinase, involved in mitogenesis 
[36,37] and suppression of ceramide-mediated apoptosis [38], 
was dependent on PTX-sensitive G proteins [39]. Finally, 
SPPC-induced activation of mitogen-activated protein kinase 
in Swiss 3T3 cells was reported to involve a PTX-sensitive G 
protein [40]. 
Based on the observation that SPPC efficiently stimulates 
superoxide production in HL-60 granulocytes and human 
neutrophils, it is likely that sphingolipids, specifically SPPC 
and its receptors, also play a role in host defense against 
invading microorganisms [15]. In line with this hypothesis is 
the recent observation that a certain Pseudomonas strain se-
cretes an enzyme capable of cleaving glycosphingolipids as 
well as sphingomyelin to produce SPPC [41]. SPPC may 
even be a candidate for clinical application, as it has been 
reported to be a potent wound healing agent in animal models 
in vivo [42]. Finally, in the studies on the regulation of L-type 
Ca2+ channels in insulinoma cells by GPS and psychosine, it 
was observed that these sphingolipids also affect insulin secre-
tion ([32] and own unpublished observations), suggesting that 
they may modulate insulin secretion in pancreatic beta cells as 
well. Thus, sphingolipids by activating specific membrane re-
ceptors can apparently regulate a wide variety of cellular func-
tions and it can be anticipated that in the near future many 
additional sphingolipid receptor-regulated processes will be 
discovered. 
2.3. Putative sphingolipid receptor subtypes 
Although a sphingolipid receptor has not been cloned so far 
or positively identified by specific binding, the present func-
tional data strongly support the notion of sphingolipid recep-
tor subtypes. A preliminary classification is given in Table 1. 
Included are only data which are comprehensive enough to 
allow a rather firm statement. Atrial myocytes apparently 
contain a Q protein-coupled receptor, which is activated 
with high affinity by both SPP and SPPC, as shown by full 
cross-desensitization of these two sphingolipids [31]. A second 
high-affinity SPP receptor, binding SPPC with ~ 500-fold 
lower affinity (or alternatively two separate receptors for 
SPP and SPPC), seems to be expressed rather widely. Activa-
tion of this receptor leads to a PTX-sensitive increase in 
[Ca2+]i in a variety of cell types [14,16]. Whether or not the 
SPP receptor described in N1E-115 cells belongs to this sub-
type is not certain, as the SPP action was PTX-insensitive and 
data on SPPC were not reported [17]. In human neutrophils 
and HL-60 granulocytes, SPPC, but not SPP, stimulated 
superoxide production and increased [Ca2+];, strongly suggest-
ing the existence of a distinct SPPC receptor, which was 
shown to couple to PTX-sensitive Gi proteins [15]. Finally, 
G protein-coupled sphingolipid receptor-mediated inhibition 
of L-type Ca2+ channels in insulinoma cells was induced by 
GPS, psychosine and SPPC in a PTX-insensitive manner, thus 
arguing for a further distinct receptor subtype [32]. Thus, 
there is not only a heterogeneity of sphingolipid receptors, 
but these receptors can obviously also couple to distinct G 
proteins, i.e. PTX-sensitive and -insensitive G proteins, the 
exact nature of these coupling proteins needs to be deter-
mined. 
In human platelets, SPP and LPA apparently share a com-
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Fig. 2. Intracellular versus receptor-mediated Ca2+ signalling by sphingolipids. PDGF, FceRI antigen and muscarinic acetylcholine (ACh) re-
ceptors activate sphingosine kinase (SPK), thus increasing intracellular SPP production. Inhibition of SPK with DHS attenuates Ca2+ release 
induced by each of the receptors indicating involvement of SPK in Ca2+ signalling. In some cell types, SPP may directly release Ca2+ from in-
tracellular stores, while in others only SPPC, but not SPP, is capable to induce Ca2+ release. SPP and SPPC also act at G protein-coupled 
plasma membrane receptors. Ca2+ release induced by the sphingolipid receptors is mainly mediated by G; proteins and involves either phospho-
lipase C stimulation or an as yet unidentified pathway. Intracellularly produced SPP may also be released to activate plasma membrane recep-
tors in an autocrine or paracrine manner. 
mon binding site, and platelet activation in response to LPA 
was desensitized by prior application of SPP [34]. Since cross-
desensitization between SPP and LPA was not observed in 
many other cell types [14,17], and cells even missing LPA 
receptors potently responded to SPP [16], it might be specu-
lated that there is a specific SPP/LPA receptor subtype in 
platelets. 
3. Intracellular action versus receptor-mediated signalling 
Apart from ceramide formation, relatively little is known 
about intracellular sphingolipid generation. SPP can be 
formed in intact cells by phosphorylation of sphingosine by 
sphingosine kinase (Fig. 2) [43], and is degraded, alternatively, 
by SPP lyase [44] or a phosphatase [45,46]. An extracellular 
stimulus reported to increase SPP formation is PDGF [36,47], 
but activation of sphingosine kinase may not be restricted to 
growth factor receptors. Recently, SPP formation was re-
ported to be involved in Ca2+ mobilization by high-affinity 
IgE receptors (FceRI) as well [18]. Preliminary data point 
towards sphingosine kinase also playing a role in Ca2+ signal-
ling by G protein-coupled receptors such as muscarinic ace-
tylcholine and bradykinin receptors [48,49]. To examine the 
role of sphingosine kinase, the two enzyme inhibitors DL-
^reodihydrosphingosine (DHS) and Af,Af-dimethylsphingo-
sine [50,51] are usually applied. However, inhibition of sphin-
gosine kinase may lead to enhanced levels of sphingosine [51], 
which in turn may be active on its own or be metabolized, e.g. 
to ceramide. 
Since SPP formation is apparently involved in Ca2+ mobi-
lization, sphingosine kinase has recently been ascribed a sim-
ilar role as phospholipase C [52]. Indeed, SPP has been shown 
to cause release of Ca2+ from intracellular stores [53,54]. 
Others, however, reported SPPC being the sphingolipid ligand 
leading to Ca2+ release from the endoplasmic reticulum 
[19,20,55]. Finally, by intracellularly forming SPP, which is 
subsequently released extracellularly, as demonstrated for hu-
man platelets [33,34], sphingosine kinase may also be indi-
rectly responsible for activation of G protein-coupled mem-
brane receptors for SPP, acting in an autocrine or paracrine 
manner. Thus, besides the plasma membrane-located G pro-
tein-coupled sphingolipid receptors inducing Ca2+ mobiliza-
tion indirectly, by stimulating phospholipase C with subse-
quent inositol 1,4,5-trisphosphate generation or other not 
yet defined mechanisms, SPP and/or SPPC can apparently 
also directly mobilize Ca2+ from intracellular stores. Future 
work will have to clarify the exact mechanisms involved in 
this putative Ca2+ signalling pathway. 
4. Future directions 
There are several open questions and urgent demands for 
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future research. First, the sources of extracellular SPP and 
other spingolipids apparently acting via specific plasma mem-
brane receptors have to be identified. Second, the mechanisms 
controlling the cellular release and, thus, the levels of extrac-
ellular sphingolipids exhibiting a wide spectrum of biological 
functions need to be characterized. Third, molecular cloning 
of the sphingolipid receptors is urgently needed for exact char-
acterization of receptor subtypes, tissue distribution, signal 
transduction and cellular functions. Finally, non-lipid agonists 
and/or antagonists have to be synthesized to activate and/or 
to block the sphingolipid receptors, possibly even suited for 
therapeutic intervention. Thus, the next decade promises to be 
an exciting period for sphingolipid research. 
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